What PSA Is — and What It Actually Measures

---

Prostate-specific antigen is a protein produced by the cells of the prostate gland — both normal prostate cells and prostate cancer cells. Its biological purpose is to liquefy semen after ejaculation.

Small amounts of PSA leak into the bloodstream, where they can be measured by a simple blood test.

The critical word in the name is "prostate-specific" — not "cancer-specific." PSA is elevated whenever the prostate is irritated, enlarged, inflamed, or disrupted, regardless of whether cancer is involved.

A urinary tract infection, a prostate biopsy, vigorous cycling, ejaculation within 48 hours, and benign prostatic hyperplasia all raise PSA.

This is the most important single fact about PSA that men do not fully understand. A raised PSA does not mean cancer.

It means the prostate is producing more PSA than usual — and cancer is one of many possible reasons why.

That said, cancer cells produce significantly more PSA per gram of tissue than normal prostate cells. So the higher the PSA, and the faster it is rising, the more likely cancer becomes as the explanation — even though it is never a certainty from a PSA result alone.

PSA at Diagnosis — What Your Initial Number Actually Means

---

Most men receive their first unexpected PSA result during a routine health check. Here is how to interpret what you are looking at, depending on where the number falls.

PSA below 4 ng/mL

This is generally considered normal. Most men below 4 ng/mL do not have prostate cancer — but "most" is not the same as "all." Approximately 15 percent of men with a PSA below 4 ng/mL will have prostate cancer if a biopsy is performed.

A small proportion of those cancers will be high-grade.

Age matters here. A PSA of 3.5 ng/mL in a 75-year-old is unremarkable. The same result in a 45-year-old with a strong family history of prostate cancer warrants closer attention. The threshold for concern is lower in younger men.

PSA velocity — how fast the PSA is rising — is often more informative than the number itself. A PSA that has risen from 1.2 to 2.8 to 3.9 over three years in a 55-year-old is more concerning than a static 3.9 in a 68-year-old.

Always look at the trend, not just the current reading.

PSA 4–10 ng/mL — the grey zone

A PSA between 4 and 10 ng/mL falls in what urologists call the grey zone. The probability of prostate cancer in this range is approximately 25 percent.

Three out of four men with a PSA in this range do not have cancer when biopsied.

In the grey zone, additional tests are used to refine the cancer probability before committing to a biopsy. The most useful is a prostate MRI — specifically a multiparametric MRI (mpMRI).

If the MRI shows no suspicious lesion, the probability of significant cancer is low enough that many urologists will monitor rather than biopsy immediately.

The PSA density — dividing the PSA level by the prostate volume measured by ultrasound — is another useful tool. A PSA density above 0.15 (ng/mL per gram of prostate) suggests cancer is more likely than BPH as the explanation for the elevated reading.

PSA above 10 ng/mL

A PSA above 10 ng/mL without a prior cancer diagnosis warrants an MRI and biopsy in almost all cases. The probability of prostate cancer rises to above 50 percent in this range.

At PSA above 20 ng/mL, the probability is above 70 percent, and the risk of locally advanced or high-grade disease increases substantially.

At PSA above 50 ng/mL, a bone scan or PSMA PET-CT to check for metastatic spread is warranted before local treatment planning. The staging investigations matter at this level because treatment for localised disease and treatment for metastatic disease are fundamentally different.

PSA on Active Surveillance — What Changes Are Worth Worrying About

---

Men on active surveillance check their PSA every three to six months. The question they ask most often is: my PSA went up — how much is too much?

The short answer: the rate of rise matters more than the absolute level. A PSA that rises from 5.2 to 5.6 over six months is not particularly concerning. A PSA that rises from 5.2 to 8.3 over the same period demands urgent re-evaluation.

The metric that oncologists use to assess the rate of rise is PSA doubling time — the time it takes for the PSA to double in value. A doubling time of more than three years is generally considered reassuring in a man on active surveillance with Gleason 6 disease.

A doubling time of less than three years is a trigger for re-evaluation, typically with a repeat MRI and biopsy.

PSA bounce on active surveillance

A PSA bounce is a temporary rise in PSA that is followed by a spontaneous fall without any change in treatment. It is a real phenomenon, documented in the published literature.

It occurs in approximately 30 to 40 percent of men on active surveillance at some point during monitoring.

Bounces are thought to be caused by inflammation in the prostate — a urinary tract infection, prostatitis, or simply the natural variation in PSA that occurs with any inflammatory process.

They can be alarming when they appear and are frequently misinterpreted as evidence of cancer progression.

The standard response to an unexpected PSA rise during active surveillance is to repeat the test in four to six weeks before drawing any conclusion. A single elevated reading is not a management trigger.

Two consecutive elevated readings, or a reading significantly above the previous trend, is the point at which re-evaluation is warranted.

PSA After Radical Prostatectomy — Understanding the Post-Surgical Rules

---

After radical prostatectomy — whether robotic or open — the prostate has been completely removed.

Since PSA is produced almost entirely by prostate cells, removing the prostate should drive PSA to undetectable levels.

The benchmark that most oncologists use for a successful surgical outcome is a PSA below 0.1 ng/mL at six weeks post-operatively. Some use 0.2 ng/mL as the threshold.

The exact threshold varies by institution — what matters is that it reaches a consistently undetectable level on your specific laboratory's assay.

Biochemical recurrence after surgery

Biochemical recurrence after radical prostatectomy is defined as a confirmed PSA of 0.2 ng/mL or above on two consecutive readings — after an initial post-operative undetectable result.

This is the earliest signal that prostate cancer cells may still be present somewhere in the body.

Biochemical recurrence does not mean the cancer has spread. It means cancer cells are producing detectable PSA — but it does not tell you where.

The PSA level at recurrence, the time elapsed since surgery, the original Gleason grade, and the PSA doubling time together help estimate whether the recurrence is local — in the prostate bed — or systemic.

A slowly rising PSA that begins rising more than two years after surgery, with a doubling time of more than twelve months, is more likely local recurrence — which is treatable with salvage radiotherapy to the prostate bed.

A rapidly rising PSA with a doubling time under six months, rising early after surgery, is more likely systemic and would prompt a PSMA PET-CT scan.

PSA After Radiation — the Nadir, the Bounce, and the Phoenix Definition

---

After radiation therapy — whether EBRT, SBRT, or brachytherapy — PSA does not drop to undetectable levels.

It falls gradually over 18 to 36 months to its lowest point, which is called the PSA nadir.

A PSA nadir below 0.5 ng/mL is associated with excellent long-term cancer control. A nadir below 0.2 ng/mL is ideal. The nadir is not usually reached until 18 months after treatment at the earliest — sometimes as late as three years.

Do not interpret early post-radiation PSA readings by the same standards you would apply to post-surgical results.

The PSA bounce after radiation

A PSA bounce — a temporary rise followed by a fall — is extremely common after radiation, particularly after brachytherapy where it occurs in approximately 30 to 40 percent of patients in the first two years.

It is caused by the radiation-induced inflammatory response in the prostate — not by cancer recurrence.

The bounce typically occurs between six and thirty months after treatment. The PSA may rise by 0.5 to 2.0 ng/mL above the nadir before falling again spontaneously.

If you notice this and your oncologist has not mentioned it, ask about it specifically — PSA bounce is one of the most common causes of unnecessary anxiety in men after radiation therapy.

The Phoenix definition of biochemical recurrence after radiation

Biochemical recurrence after radiation is defined differently from after surgery. The Phoenix definition — the internationally accepted standard — defines recurrence as a PSA rise of 2 ng/mL above the nadir.

If your nadir was 0.4 ng/mL, a PSA rise to 2.4 ng/mL constitutes recurrence under the Phoenix definition. If your nadir was 0.1 ng/mL, a rise to 2.1 ng/mL is the threshold.

The key point is that the threshold is relative to the nadir — not a fixed absolute number.

This is why a post-radiation PSA of 1.8 ng/mL might be entirely consistent with a normal treatment response in one patient, and might represent recurrence in another — depending entirely on where their individual nadir sits.

PSA on Hormone Therapy — What to Expect During ADT

---

Androgen deprivation therapy works by suppressing the testosterone that prostate cancer cells depend on for growth. When testosterone falls, prostate cancer cells stop proliferating and many die — and PSA falls in response.

Most men starting LHRH injections see their PSA fall by 90 to 99 percent within three to six months. A PSA below 0.2 ng/mL after ADT induction is considered a good response.

A PSA below 0.1 ng/mL is ideal and associated with better long-term outcomes.

The PSA is monitored every three months during ADT. A PSA that continues rising despite confirmed castrate testosterone levels — below 50 ng/dL — is the definition of castration-resistant prostate cancer (CRPC).

This is a clinical turning point that requires a change in treatment strategy — typically the addition of abiraterone, enzalutamide, or another second-generation hormonal agent.

PSA flare at the start of ADT

In the first two to four weeks after starting an LHRH agonist — leuprolide or goserelin — the PSA may actually rise before it falls. This is called testosterone flare.

It is the brief surge in testosterone production that occurs before the LHRH agonist's suppressive effect takes hold.

PSA flare is expected and does not mean the treatment is failing.

It is the reason many oncologists prescribe a brief course of a testosterone-blocking agent — bicalutamide — starting one week before the first LHRH injection, to prevent the flare from stimulating cancer growth during that initial window.

How to Monitor PSA From Home — a Practical Guide for International Patients

---

For international patients who had treatment in India and returned home, PSA monitoring is the primary ongoing connection between you and your treating oncologist. Getting it right practically matters.

Use the same laboratory every time

PSA assays vary between laboratories. A result of 0.08 ng/mL at Laboratory A and 0.12 ng/mL at Laboratory B may reflect nothing more than the difference in assay sensitivity between the two labs — not a genuine change in your PSA.

Testing at different laboratories makes the trend meaningless.

Choose a single reliable laboratory near you and use it consistently for every PSA test. When sending results to your Indian oncologist, always include the laboratory name and the assay version — this context matters for interpretation.

Know your monitoring schedule

After radical prostatectomy: PSA at six weeks post-operatively, then every three months for two years, then every six months for years three to five, then annually thereafter if stable.

After radiation: PSA every three to six months for the first two to three years while the nadir is being established, then every six months for years three to five, then annually if stable.

On active surveillance: PSA every three to six months throughout the surveillance period, more frequently if results are trending upward.

On ADT: PSA every three months with testosterone level measured at the same time to confirm ongoing castrate levels.

Do not test within 48 hours of ejaculation

Ejaculation temporarily raises PSA by up to 0.5 ng/mL. For men with PSA levels below 1 ng/mL post-surgery — where a 0.2 ng/mL rise is clinically meaningful — this can produce a falsely concerning result.

Abstain from ejaculation for 48 to 72 hours before a PSA test.

Similarly, do not test PSA within three to four weeks of a prostate biopsy, vigorous cycling, or prostate massage — all of which temporarily elevate the reading in ways that make interpretation unreliable.

Frequently Asked Questions

---